Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Cancers (Basel). 2023 Sep 28;15(19):4769. doi: 10.3390/cancers15194769.


The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.

Keywords: laparoscopic surgery; minimally-invasive surgery; recurrent ovarian cancer; robotic surgery; secondary cytoreductive surgery.

Publication types

  • Review

Grants and funding

This research received no external funding.